VOLITIONRX LTD (VNRX): Unregistered Sales of Equity Securities
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management X
How this was made
The 30-second read
Why it matters
The company issued common shares to Lind Global Asset Management XII LLC to satisfy obligations under senior secured convertible promissory notes, relying on securities-law exemptions.
Market read
This is a concrete dilution/supply datapoint from a convertible-note structure, disclosed via SEC filing timing and specific share counts.
What to watch
Traders should distinguish between dilution from conversions versus any concurrent catalysts (clinical, financing terms, or cash runway) not covered in this filing excerpt.
Background
The 8-K Item 3.02 reports unregistered sales of equity securities under a securities purchase agreement dated May 15, 2025, amended January 7, 2026.
Ticker impact
VolitionRx filed an 8-K for unregistered sales, issuing common shares to Lind Global to satisfy convertible note obligations.
Near-term pressure is possible if traders focus on dilution, but the impact may be limited because the shares are issued to satisfy specific conversion/payment obligations.
Item 3.02 specifies three share issuances (July 14, July 16, and Aug 6, 2026) totaling 779,371 shares to Lind for note-related obligations, which is a concrete dilution/supply datapoint.
Market effects
Convertible note conversions and related share issuances are a common overhang risk for small-cap biotech and life-science issuers.
No clear regional spillover beyond US-listed small-cap sentiment.
Limited, as the disclosure is company-specific and not a cross-border deal or regulatory action.
Counterpoint
If the market views the convertible structure as already priced in, the incremental share issuance may not materially change valuation expectations.
Key entities
- issuerVolitionRx Limited
Subject of the SEC 8-K reporting unregistered sales of equity securities tied to convertible notes.
- counterpartyLind Global Asset Management XII LLC
Receives common shares issued to satisfy conversion/payment obligations under the SPA and notes.
